Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register

Objective To compare the 10-year outcome (disease activity, disability, mortality) of two cohorts of patients with inflammatory polyarthritis (IP) recruited 10 years apart. Methods Patients with IP were recruited to the Norfolk Arthritis Register from 1990 to 1994 (cohort 1 (C1)) and from 2000 to 2004 (cohort 2 (C2)). Demographic and clinical data were collected at baseline and at years 1, 2, 3, 5, 7 and 10. Longitudinal disease activity (swollen/tender 51 joint counts (SJC51/TJC51)) and disability (Health Assessment Questionnaire (HAQ)) were compared between the cohorts using population-average negative binomial regression and generalised estimating equation analysis, respectively. Risk of 10-year mortality was compared between cohorts using Cox models. Risk of cardiovascular disease (CVD) mortality was compared between cohorts using competing risks analysis. Mortality rate ratios (MRR), adjusted for changes in mortality risk of the general population, were calculated using Poisson regression. Results In total 1653 patients were recruited (C1=1022, C2=631). Patients in C2 had 17% lower SJC51 than C1 over 10 years (95% CI −23% to −10%), whereas TJC51 and HAQ were comparable. C2 patients had reduced risk of all-cause and CVD mortality compared with C1 (all-cause: HR 0.72, 95% CI 0.56 to 0.95; CVD: subhazard ratio 0.58, 95% CI 0.37 to 0.93). After accounting for changes in mortality risk in the general population, the difference in mortality was non-significant (all-cause: MRR 0.78, 95% CI 0.56 to 1.10; CVD: MRR 0.77, 95% CI 0.48 to 1.24). Conclusion Disease activity significantly improved in the new millennium, whereas disability and mortality were unchanged.

[1]  A. Kiadaliri,et al.  Brief Report: Rheumatoid Arthritis as the Underlying Cause of Death in Thirty‐One Countries, 1987–2011: Trend Analysis of World Health Organization Mortality Database , 2017, Arthritis & rheumatology.

[2]  M. Lunt,et al.  Twenty‐Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register , 2017, Arthritis & rheumatology.

[3]  T. Therneau,et al.  Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA? , 2017, The Journal of Rheumatology.

[4]  S. Norton,et al.  Secular Changes in Clinical Features at Presentation of Rheumatoid Arthritis: Increase in Comorbidity But Improved Inflammatory States , 2017, Arthritis care & research.

[5]  C. Bombardier,et al.  Trends in Excess Mortality Among Patients With Rheumatoid Arthritis in Ontario, Canada , 2015, Arthritis care & research.

[6]  M. Lunt,et al.  Mortality Trends in Patients With Early Rheumatoid Arthritis Over 20 Years: Results From the Norfolk Arthritis Register , 2014, Arthritis care & research.

[7]  M. Lunt,et al.  Has the Severity of Rheumatoid Arthritis at Presentation Diminished Over Time? , 2014, The Journal of Rheumatology.

[8]  M. P. Lozano,et al.  FRI0296 Is There A Difference in the Effectiveness in the Treatment of Rheumatoid Arthritis with Rituximab in Patients with Rheumatoid Factor Positive and Negative? A Systematic Review , 2014 .

[9]  Désirée van der Heijde,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update , 2013, Annals of the rheumatic diseases.

[10]  P. Emery,et al.  Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis , 2013, Annals of the rheumatic diseases.

[11]  D. M. van der Heijde,et al.  Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivi des polyarthrites indifférenciées récentes (study and followup of early undifferentiated polyarthritis). , 2011, Arthritis and rheumatism.

[12]  John Wong,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs , 2010, Annals of the rheumatic diseases.

[13]  A. Davis,et al.  Patient Satisfaction after Total Knee Arthroplasty: Who is Satisfied and Who is Not? , 2010, Clinical orthopaedics and related research.

[14]  D. Symmons,et al.  Mortality in established rheumatoid arthritis. , 2007, Best practice & research. Clinical rheumatology.

[15]  M. Liang,et al.  Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. , 2006, Arthritis and rheumatism.

[16]  P. V. van Riel,et al.  Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. , 2005, Arthritis and rheumatism.

[17]  Andrea Messori,et al.  New drugs for rheumatoid arthritis [6] (multiple letters) , 2004 .

[18]  L. Kay,et al.  Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study. , 2004, Rheumatology.

[19]  N. Olsen,et al.  New drugs for rheumatoid arthritis. , 2004, The New England journal of medicine.

[20]  T. Pincus,et al.  Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. , 2003, Clinical and experimental rheumatology.

[21]  J. Arokoski,et al.  Osteoarthritis of finger joints in Finns aged 30 or over: prevalence, determinants, and association with mortality , 2003, Annals of the rheumatic diseases.

[22]  E. Cook,et al.  The importance of patient expectations in predicting functional outcomes after total joint arthroplasty. , 2002, The Journal of rheumatology.

[23]  James M Robins,et al.  Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study , 2002, The Lancet.

[24]  Alison J. Carr,et al.  An Ethical Dilemma Medical Errors and Medical Culture an Error of Omission Education and Debate , 2022 .

[25]  A. Silman,et al.  Reduced disability at five years with early treatment of inflammatory polyarthritis: results from a large observational cohort, using propensity models to adjust for disease severity. , 2001, Arthritis and rheumatism.

[26]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[27]  A. Silman,et al.  The incidence of rheumatoid arthritis in the United Kingdom: results from the Norfolk Arthritis Register. , 1994, British journal of rheumatology.

[28]  J. Kirwan,et al.  Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. , 1986, British journal of rheumatology.

[29]  Laure Gossec,et al.  Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis. , 2013, Joint, bone, spine : revue du rhumatisme.

[30]  Mark Lunt,et al.  Early treatment with , and time receiving , fi rst disease-modifying antirheumatic drug predicts long-term function in patients with infl ammatory polyarthritis , 2010 .

[31]  A. Silman,et al.  Rheumatoid arthritis classifi cation criteria : an American College of Rheumatology / European League Against Rheumatism collaborative initiative , 2010 .

[32]  A. Silman,et al.  Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. , 2003, Arthritis and rheumatism.

[33]  O Wiegman,et al.  Determinants of compliance with medication in patients with rheumatoid arthritis: the importance of self-efficacy expectations. , 1999, Patient Education and Counseling.